Ultra-Early Phase pathologies of Alzheimer's disease and other neurodegenerative diseases

Access this Article

Author(s)

    • OKAZAWA Hitoshi OKAZAWA Hitoshi
    • Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University

Abstract

<p>The concept of neurodegenerative diseases and the therapeutics targeting these intractable diseases are changing rapidly. Protein aggregation as the top of pathological cascade is now challenged, and many alternative ideas are proposed. Early molecular pathologies before microscopic detection of diseases protein aggregates, which I propose to call "Ultra-Early Phase pathologies or phase 0 pathologies", are the focus of research that might explain the failures of clinical trials with anti-Aβ antibodies against Alzheimer's disease. In this review article, I summarize the critical issues that should be successfully and consistently answered by a new concept of neurodegeneration. For reevaluating old concepts and reconstructing a new concept of neurodegeneration that will replace the old ones, non-biased comprehensive approaches including proteome combined with systems biology analyses will be a powerful tool. I introduce our recent efforts in this orientation that have reached to the stage of non-clinical proof of concept applicable to clinical trials.</p>

Journal

  • Proceedings of the Japan Academy, Series B

    Proceedings of the Japan Academy, Series B 93(6), 361-377, 2017

    The Japan Academy

Codes

  • NII Article ID (NAID)
    130005696850
  • NII NACSIS-CAT ID (NCID)
    AA00785485
  • Text Lang
    ENG
  • ISSN
    0386-2208
  • NDL Article ID
    028342948
  • NDL Call No.
    Z53-T495
  • Data Source
    NDL  J-STAGE 
Page Top